At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CUE Cue Biopharma, Inc.
Trading 08-26 14:35:52 EDT
27.25
+0.49
+1.83%
High27.83Low26.26Vol93.04K
Open26.63D1 Closing26.76Amplitude5.87%
Mkt Cap197.95MTradable Cap175.80MTotal Shares7.26M
T/O2.51MT/O Rate1.44%Tradable Shares6.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adial Pharmaceuticals Posts Bigger-than-Expected Q2 Net Loss, Hurt by Acquisition Charges
Reuters  ·  08-17
Adial Pharmaceuticals Posts Bigger-than-Expected Q2 Net Loss, Hurt by Acquisition Charges
Cue Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-15
Cue Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
THOMSON REUTERS  ·  08-15
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma Q2 EPS $-24.14
THOMSON REUTERS  ·  08-15
Cue Biopharma Q2 EPS $-24.14
Cue Biopharma Q2 FY26 Net Loss Widens to $153.07 Million; Revenue Rises 162.61% to $7.88 Million
Reuters  ·  08-15
Cue Biopharma Q2 FY26 Net Loss Widens to $153.07 Million; Revenue Rises 162.61% to $7.88 Million
Cue Biopharma - Proposed Resale of up to 1,505,570 Shares of Common Stock by Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  08-13
Cue Biopharma - Proposed Resale of up to 1,505,570 Shares of Common Stock by Selling Stockholders - SEC Filing
Cue Biopharma, Inc. Expected to Post a Loss of $1.69 a Share - Earnings Preview
Reuters  ·  08-08
Cue Biopharma, Inc. Expected to Post a Loss of $1.69 a Share - Earnings Preview
Cue Biopharma CFO James M. Ahlers Files Initial Beneficial Ownership Statement
Reuters  ·  08-04
Cue Biopharma CFO James M. Ahlers Files Initial Beneficial Ownership Statement
Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Dow Jones  ·  08-03
Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Cue Biopharma Files Form 3 for Chief Medical Officer, Head of R&D Dominique Borie
Reuters  ·  07-16
Cue Biopharma Files Form 3 for Chief Medical Officer, Head of R&D Dominique Borie
Cue Biopharma Names Dominic Borie Chief Medical Officer, Head of R&D
Reuters  ·  07-13
Cue Biopharma Names Dominic Borie Chief Medical Officer, Head of R&D
Cue Biopharma Appoints Dominic Borie, M.d., Ph.d., as Chief Medical Officer and Head of Research & Development
THOMSON REUTERS  ·  07-13
Cue Biopharma Appoints Dominic Borie, M.d., Ph.d., as Chief Medical Officer and Head of Research & Development
Top Midday Gainers
MT Newswires Live  ·  07-11
Top Midday Gainers
Cue Biopharma to sell 1.418M shares at $33.21 in private placement
TIPRANKS  ·  07-10
Cue Biopharma to sell 1.418M shares at $33.21 in private placement
Cue Biopharma Announces USD 50 Million Private Placement of Unregistered Shares and Pre-funded Warrants
Reuters  ·  07-10
Cue Biopharma Announces USD 50 Million Private Placement of Unregistered Shares and Pre-funded Warrants
Cue Biopharma Announces $50.0 Million Private Placement
THOMSON REUTERS  ·  07-10
Cue Biopharma Announces $50.0 Million Private Placement
Cue Biopharma Files for Shares Sale by Shareholder
MT Newswires Live  ·  06-19
Cue Biopharma Files for Shares Sale by Shareholder
Cue Biopharma files to sell 551,724 shares of common stock for holders
TIPRANKS  ·  06-19
Cue Biopharma files to sell 551,724 shares of common stock for holders
Cue Biopharma files initial beneficial ownership statement for VP, principal accounting officer Michael Meluzio
Reuters  ·  06-12
Cue Biopharma files initial beneficial ownership statement for VP, principal accounting officer Michael Meluzio
Cue Biopharma Chief Legal Compliance Officer Ray Sumita files initial beneficial ownership statement
Reuters  ·  06-12
Cue Biopharma Chief Legal Compliance Officer Ray Sumita files initial beneficial ownership statement

Introduction

Company Name.
Cue Biopharma, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Issue price:
--